An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Inclusion Criteria

• •A minimum of 12 months of continuous enrolment in the databases with medical and pharmacy coverage measured as continuously receiving medical care from health providers contributing to the EHR or claims system, depending on the database used
• •No recorded prescription for finerenone in the 12 months prior to the index date
• •Age of 18 years or older as of the index date
• •Evidence of T2D at any point before (and including) the index date.
• •CKD stages 2-4 related to eligibility will be defined according to the presence of the following criteria at any point before (and including) the index date:
• •* A diagnosis code indicating CKD stage 2, 3, 4 or stage unspecified
• •* two UACR tests results ≥ 30 mg/g separated by at least 90 days and by not more than 540 days
• •* two different eGFR test results ≥ 15 mL/min/1.73 m2 AND \< 60 mL/min/1.73 m2 separated by at least 90 days and by not more than 540 days